Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 6:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: DMS Clear all
Completed Early Phase 1 Interventional

Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)

NCT01091792
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Bevacizumab
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Sep 10, 2026, 6:42 AM EDT
Withdrawn Phase 2 Interventional

Mercury Chelation to Treat Autism

NCT00376194
View directory record Official record
Conditions
Autism, Asperger's Disorder, Child Development Disorders, Pervasive
Interventions
DMSA
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
4 Years to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Sep 10, 2026, 6:42 AM EDT
Completed Phase 1Phase 2 Interventional

Dimercaptosuccinic Acid (DMSA) Treatment of Children With Autism and Heavy Metal Toxicity

NCT00811083
View directory record Official record
Conditions
Autism
Interventions
DMSA - dimercaptosuccinic acid
Drug
Lead sponsor
Southwest College of Naturopathic Medicine
Other
Eligibility
3 Years to 8 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 17, 2008 · Synced Sep 10, 2026, 6:42 AM EDT
Completed Phase 3 Interventional

Treatment of Lead-Exposed Children Trial

NCT00342849
View directory record Official record
Conditions
Lead Exposure
Interventions
Succimer, Placebo
Drug
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
12 Months to 33 Months
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2015
U.S. locations
4
States / cities
Baltimore, Maryland • Newark, New Jersey • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 10, 2026, 6:42 AM EDT
Not listed Phase 4 Interventional

DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole

NCT03881449
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder, Bi-Polar Disorder, Schizo Affective Disorder
Interventions
ABILIFY MYCITE
Combination Product
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Sep 10, 2026, 6:42 AM EDT
Completed Phase 1 Interventional

A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies

NCT00923520
View directory record Official record
Conditions
Renal Cell Carcinoma, Breast Cancer, Colon Cancer, Lung Cancer, Non-Hodgkin Lymphoma
Interventions
DMS 612
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
3
States / cities
Bethesda, Maryland • Hershey, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 10, 2026, 6:42 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of USP Methylene Blue on Cognitive and fMRI Brain Activity

NCT01836094
View directory record Official record
Conditions
Brain Activity
Interventions
Methylene Blue (USP grade, 280mg oral), Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 10, 2026, 6:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Detecting Drugs of Abuse Via Exhaled Breath Samples Using Differential Mobility Spectrometry

NCT05384470
View directory record Official record
Conditions
Opiate Abuse, Marijuana Abuse, Diagnostic
Interventions
Marihuana, BID2 Instrument - breathalyzer
Drug · Device
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 10, 2026, 6:42 AM EDT
Active, not recruiting No phase listed Observational

ADH1 and ADH2 Disease Monitoring Study (DMS)

NCT05227287
View directory record Official record
Conditions
Autosomal Dominant Hypocalcemia
Interventions
Not listed
Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Industry
Eligibility
Up to 90 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
9
States / cities
Oakland, California • Aurora, Colorado • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 10, 2026, 6:42 AM EDT
Completed Not applicable Interventional Results available

Accu-Chek® CONNECT at School (CATS) Pediatric Study

NCT02609633
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Accu-Chek® CONNECT DMS, DMS
Device
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
7 Years to 18 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
13
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Sep 10, 2026, 6:42 AM EDT
Completed Phase 2 Interventional

Efficacy of Injection Therapy for Lateral Epicondylosis

NCT01476605
View directory record Official record
Conditions
Tennis Elbow
Interventions
Dextrose prolotherapy, PrT-DMS, Platelet Rich Plasma injection
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 17, 2019 · Synced Sep 10, 2026, 6:42 AM EDT
Not yet recruiting No phase listed Observational

Clinical Investigation Plan - Post-market Clinical Follow-up Study Collagen Dura Membrane - Suturable

NCT07217132
View directory record Official record
Conditions
Repair of Dura Mater
Interventions
Post-market Study
Other
Lead sponsor
Collagen Matrix
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Timeline
2025 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 10, 2026, 6:42 AM EDT
Completed Not applicable Interventional Results available

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)

NCT05174312
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Reprieve Decongestion Management System, Diuretic
Device · Drug
Lead sponsor
Reprieve Cardiovascular, Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
16
States / cities
Fairhope, Alabama • Irvine, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 10, 2026, 6:42 AM EDT
Completed Not applicable Interventional

POLARx Post Approval Study (POLARx PAS)

NCT06170606
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
Boston Scientific Cardiac Cryoablation System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 10, 2026, 6:42 AM EDT
Recruiting Phase 1 Interventional

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

NCT03630991
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Very High Risk Myelodysplastic Syndrome
Interventions
Edetate Calcium Disodium, Multivitamin, Succimer
Drug · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 10, 2026, 6:42 AM EDT
Recruiting Phase 2 Interventional

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

NCT06811233
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
DMSA, Ca-EDTA, Magnesium Sulfate, Multivitamin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 10, 2026, 6:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS)

NCT02018250
View directory record Official record
Conditions
Safety and Efficacy
Interventions
MMB4 DMS, Placebo
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Sep 10, 2026, 6:42 AM EDT
Completed Not applicable Interventional Results available

Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation

NCT04133168
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
Boston Scientific Cardiac Cryoablation System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 10, 2026, 6:42 AM EDT